Standout Papers
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021)
- Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023)
- Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025)
Immediate Impact
1 from Science/Nature 56 standout
Citing Papers
Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021
2025 Standout
Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications
2025 Standout
Works of Brittany de Temple being referenced
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2023 Standout
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
2021 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Brittany de Temple | 356 | 192 | 113 | 193 | 9 | 469 | |
| Erica Fong | 325 | 175 | 103 | 174 | 7 | 437 | |
| Jacqueline Williams | 373 | 142 | 110 | 141 | 8 | 471 | |
| Martín Garaycoechea | 334 | 154 | 74 | 159 | 11 | 420 | |
| Rizwana Mohseni | 380 | 122 | 111 | 210 | 6 | 455 | |
| Ryan S. Huss | 334 | 119 | 147 | 148 | 14 | 479 | |
| Marc Elías | 404 | 167 | 85 | 187 | 10 | 553 | |
| Michael Charlton | 268 | 153 | 137 | 88 | 10 | 471 | |
| Hiroshi Ishiba | 411 | 124 | 148 | 251 | 18 | 531 | |
| Xiaomin Pan | 264 | 160 | 93 | 105 | 16 | 562 | |
| Michael Dudek | 275 | 164 | 75 | 83 | 11 | 445 |
All Works
Loading papers...